These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 24993163)
21. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts. Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674 [TBL] [Abstract][Full Text] [Related]
22. Assessment of V600E mutation of BRAF gene and rate of cell proliferation using fine-needle aspirates from metastatic melanomas. Sviatoha V; Tani E; Ghaderi M; Kleina R; Skoog L Anticancer Res; 2010 Sep; 30(9):3267-72. PubMed ID: 20944096 [TBL] [Abstract][Full Text] [Related]
23. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942 [TBL] [Abstract][Full Text] [Related]
24. BRAF V600E mutation mediates invasive and growth features in ameloblastoma. Zhang CX; Zhang LZ; Lin H; Man QW; Liu B Oral Dis; 2024 Oct; 30(7):4426-4439. PubMed ID: 38424736 [TBL] [Abstract][Full Text] [Related]
25. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847 [TBL] [Abstract][Full Text] [Related]
26. The importance of BRAF-V600E mutation to ameloblastoma metabolism. Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334 [TBL] [Abstract][Full Text] [Related]
27. Genetic study of the BRAF gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. Soltani M; Tabatabaiefar MA; Mohsenifar Z; Pourreza MR; Moridnia A; Shariati L; Razavi SM J Oral Pathol Med; 2018 Jan; 47(1):86-90. PubMed ID: 28650588 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. Brown NA; Betz BL; Weigelin HC; Elenitoba-Johnson KS; Lim MS; Bailey NG Am J Clin Pathol; 2015 Jan; 143(1):89-99. PubMed ID: 25511147 [TBL] [Abstract][Full Text] [Related]
29. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305 [TBL] [Abstract][Full Text] [Related]
30. The molecular basis of odontogenic cysts and tumours. Gomes IP; Bastos VC; Guimarães LM; Gomes CC J Oral Pathol Med; 2023 Apr; 52(4):351-356. PubMed ID: 36629457 [TBL] [Abstract][Full Text] [Related]
32. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related]
33. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088 [TBL] [Abstract][Full Text] [Related]
34. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205 [TBL] [Abstract][Full Text] [Related]
35. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. You Z; Liu SP; Du J; Wu YH; Zhang SZ J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659 [TBL] [Abstract][Full Text] [Related]
36. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709 [TBL] [Abstract][Full Text] [Related]
38. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757 [TBL] [Abstract][Full Text] [Related]
39. Mutations in PIK3CA are infrequent in neuroblastoma. Dam V; Morgan BT; Mazanek P; Hogarty MD BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308 [TBL] [Abstract][Full Text] [Related]
40. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]